Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings (HRMY)
NASDAQ:HRMY
HRMY Analyst Ratings
Strong Buy
9 Buy
0 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
HRMY Stock 12 Month Forecast
Average Price Target
$44.67
▲(56.35% Upside)
| Highest Price Target$62.00 | Average Price Target$44.67 | Lowest Price Target$31.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Mizuho Securities
$35→$36
Buy
26.01%
Upside
Reiterated
10/29/25
Truist Financial
―
Buy
―
Reiterated
10/24/25
H.C. Wainwright
$55
Buy
92.51%
Upside
Reiterated
10/23/25
Harmony Biosciences Holdings: Strong Financial Performance and Promising Pipeline Drive Buy RatingValuation and Risks. We assess Harmony using a discounted cash flow (DCF)- and sum-of-the-parts (SOTP)- based methodology. We assign probabilities of success to pitolisant GR in NT1, NT2, and IH of 60%, pitolisant HD in NT1, NT2, and IH of 60%, EPX100 in Dravet syndrome of 80%, and EPX100 in Lennox-Gastaux syndrome of 80%. We employ a 12% discount rate and a terminal multiple of 6.0x. Taken together, these assumptions yield a total firm value of approximately $3B and price target of $55.
Needham
$41
Buy
43.51%
Upside
Reiterated
10/23/25
UBS
$50→$43
Buy
50.51%
Upside
Reiterated
10/14/25
Deutsche Bank
$54→$36
Buy
26.01%
Upside
Reiterated
09/25/25
Piper Sandler
$48
Buy
68.01%
Upside
Reiterated
09/25/25
Cantor Fitzgerald
$54→$50
Buy
75.01%
Upside
Reiterated
09/24/25
Bank of America Securities
$31
Sell
8.51%
Upside
Reiterated
09/24/25
Sell Rating for Harmony Biosciences: Setbacks in R&D and Uncertain Pipeline OutlookWe had excluded the FXS opportunity from our model on assumption of high study risk; thus HRMY’s discontinuation of ZYN002 development has no model impact. We maintain our Underperform rating driven by the speculative pipeline ahead of Wakix LOE.
Oppenheimer
$70→$62
Buy
117.01%
Upside
Reiterated
09/24/25
Goldman Sachs
$33
Hold
15.51%
Upside
Initiated
07/10/25
LifeSci Capital
$61
Buy
113.51%
Upside
Reiterated
04/08/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Mizuho Securities
$35→$36
Buy
26.01%
Upside
Reiterated
10/29/25
Truist Financial
―
Buy
―
Reiterated
10/24/25
H.C. Wainwright
$55
Buy
92.51%
Upside
Reiterated
10/23/25
Harmony Biosciences Holdings: Strong Financial Performance and Promising Pipeline Drive Buy RatingValuation and Risks. We assess Harmony using a discounted cash flow (DCF)- and sum-of-the-parts (SOTP)- based methodology. We assign probabilities of success to pitolisant GR in NT1, NT2, and IH of 60%, pitolisant HD in NT1, NT2, and IH of 60%, EPX100 in Dravet syndrome of 80%, and EPX100 in Lennox-Gastaux syndrome of 80%. We employ a 12% discount rate and a terminal multiple of 6.0x. Taken together, these assumptions yield a total firm value of approximately $3B and price target of $55.
Needham
$41
Buy
43.51%
Upside
Reiterated
10/23/25
UBS
$50→$43
Buy
50.51%
Upside
Reiterated
10/14/25
Deutsche Bank
$54→$36
Buy
26.01%
Upside
Reiterated
09/25/25
Piper Sandler
$48
Buy
68.01%
Upside
Reiterated
09/25/25
Cantor Fitzgerald
$54→$50
Buy
75.01%
Upside
Reiterated
09/24/25
Bank of America Securities
$31
Sell
8.51%
Upside
Reiterated
09/24/25
Sell Rating for Harmony Biosciences: Setbacks in R&D and Uncertain Pipeline OutlookWe had excluded the FXS opportunity from our model on assumption of high study risk; thus HRMY’s discontinuation of ZYN002 development has no model impact. We maintain our Underperform rating driven by the speculative pipeline ahead of Wakix LOE.
Oppenheimer
$70→$62
Buy
117.01%
Upside
Reiterated
09/24/25
Goldman Sachs
$33
Hold
15.51%
Upside
Initiated
07/10/25
LifeSci Capital
$61
Buy
113.51%
Upside
Reiterated
04/08/25
Best Analysts Covering Harmony Biosciences Holdings
1 Month
xxx
Success Rate
9/14 ratings generated profit
Average Return
+6.17%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of +6.17% per trade.
3 Months
xxx
Success Rate
9/14 ratings generated profit
Average Return
+6.14%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +6.14% per trade.
1 Year
Success Rate
7/14 ratings generated profit
Average Return
+0.61%
reiterated a buy rating 7 months ago
Copying Francois Brisebois's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +0.61% per trade.
2 Years
xxx
Success Rate
3/15 ratings generated profit
Average Return
-15.53%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 20.00% of your transactions generating a profit, with an average return of -15.53% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
HRMY Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
10
8
7
10
9
Buy
11
17
19
21
19
Hold
0
1
1
1
0
Sell
2
1
0
1
1
Strong Sell
0
0
0
0
0
total
23
27
27
33
29
Each month's total comprises the sum of three months' worth of ratings.
HRMY Financial Forecast
HRMY Stock Forecast FAQ
What is HRMY’s average 12-month price target, according to analysts?
Based on analyst ratings, Harmony Biosciences Holdings’s 12-month average price target is 44.67.
What is HRMY’s upside potential, based on the analysts’ average price target?
Harmony Biosciences Holdings has 56.35% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is HRMY a Buy, Sell or Hold?
Harmony Biosciences Holdings has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 1 sell ratings.
What is Harmony Biosciences Holdings’s price target?
The average price target for Harmony Biosciences Holdings is 44.67. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $62.00 ,the lowest forecast is $31.00. The average price target represents 56.35% Increase from the current price of $28.57.
The highest analyst price target is $62.00 ,the lowest forecast is $31.00. The average price target represents 56.35% Increase from the current price of $28.57.
What do analysts say about Harmony Biosciences Holdings?
Harmony Biosciences Holdings’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of HRMY?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.